English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Cardiac-specific succinate dehydrogenase deficiency in Barth syndrome.

MPS-Authors
There are no MPG-Authors in the publication available
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

2253010.pdf
(Publisher version), 3MB

Supplementary Material (public)

2253010_Suppl_1.pdf
(Supplementary material), 236KB

2253010_Suppl_3.zip
(Supplementary material), 9MB

2253010_Suppl_4.zip
(Supplementary material), 6MB

2253010_Suppl_5.zip
(Supplementary material), 4MB

2253010_Suppl_2.zip
(Supplementary material), 31MB

Citation

Dudek, J., Cheng, I. F., Chowdhury, A., Wozny, K., Balleininger, M., Reinhold, R., et al. (2015). Cardiac-specific succinate dehydrogenase deficiency in Barth syndrome. EMBO Molecular Medicine, 8(2), 139-154. doi:10.15252/emmm.201505644.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0029-C6F7-8
Abstract
Barth syndrome (BTHS) is a cardiomyopathy caused by the loss of tafazzin, a mitochondrial acyltransferase involved in the maturation of the glycerophospholipid cardiolipin. It has remained enigmatic as to why a systemic loss of cardiolipin leads to cardiomyopathy. Using a genetic ablation of tafazzin function in the BTHS mouse model, we identified severe structural changes in respiratory chain supercomplexes at a pre-onset stage of the disease. This reorganization of supercomplexes was specific to cardiac tissue and could be recapitulated in cardiomyocytes derived from BTHS patients. Moreover, our analyses demonstrate a cardiac-specific loss of succinate dehydrogenase (SDH), an enzyme linking the respiratory chain with the tricarboxylic acid cycle. As a similar defect of SDH is apparent in patient cell-derived cardiomyocytes, we conclude that these defects represent a molecular basis for the cardiac pathology in Barth syndrome.